Phreesia’s (PHR) “Buy” Rating Reiterated at Truist Financial

Truist Financial restated their buy rating on shares of Phreesia (NYSE:PHR) in a research note released on Monday, Benzinga reports. Truist Financial currently has a $29.00 price target on the stock.

A number of other analysts have also issued reports on the company. Royal Bank of Canada reaffirmed a sector perform rating and set a $23.00 target price on shares of Phreesia in a research report on Thursday, March 21st. Robert W. Baird boosted their price objective on Phreesia from $30.00 to $31.00 and gave the stock an outperform rating in a research report on Monday, March 18th. Raymond James reiterated an outperform rating and set a $30.00 price objective (up from $25.00) on shares of Phreesia in a research report on Friday, March 15th. Canaccord Genuity Group cut their target price on Phreesia from $37.00 to $34.00 and set a buy rating for the company in a research report on Friday, May 31st. Finally, DA Davidson reiterated a neutral rating and set a $32.00 price objective on shares of Phreesia in a research report on Friday, March 15th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $30.92.

Phreesia Price Performance

Shares of NYSE:PHR opened at $20.68 on Monday. The company has a market cap of $1.19 billion, a P/E ratio of -9.53 and a beta of 0.92. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.03. Phreesia has a 52 week low of $12.05 and a 52 week high of $34.98. The business has a fifty day simple moving average of $21.31 and a 200-day simple moving average of $23.22.

Phreesia (NYSE:PHR) last issued its earnings results on Thursday, May 30th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.16. The firm had revenue of $101.20 million for the quarter, compared to analysts’ expectations of $100.94 million. Phreesia had a negative return on equity of 46.89% and a negative net margin of 31.87%. The firm’s revenue for the quarter was up 20.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.70) earnings per share. Equities research analysts forecast that Phreesia will post -1.18 EPS for the current year.

Insider Activity at Phreesia

In related news, CEO Chaim Indig sold 3,392 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $22.86, for a total value of $77,541.12. Following the completion of the transaction, the chief executive officer now owns 1,222,005 shares of the company’s stock, valued at $27,935,034.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO Chaim Indig sold 3,392 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $22.86, for a total transaction of $77,541.12. Following the completion of the sale, the chief executive officer now owns 1,222,005 shares of the company’s stock, valued at $27,935,034.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, General Counsel Allison C. Hoffman sold 1,238 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $22.86, for a total transaction of $28,300.68. Following the completion of the sale, the general counsel now directly owns 135,621 shares of the company’s stock, valued at approximately $3,100,296.06. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 50,359 shares of company stock worth $1,141,645. Company insiders own 5.80% of the company’s stock.

Institutional Trading of Phreesia

A number of hedge funds and other institutional investors have recently modified their holdings of PHR. International Assets Investment Management LLC boosted its stake in Phreesia by 1,987.3% in the fourth quarter. International Assets Investment Management LLC now owns 1,482 shares of the company’s stock valued at $34,000 after acquiring an additional 1,411 shares during the last quarter. Acadian Asset Management LLC bought a new position in shares of Phreesia during the third quarter worth $53,000. Russell Investments Group Ltd. raised its holdings in shares of Phreesia by 5,462.3% during the fourth quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock worth $89,000 after acquiring an additional 3,769 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Phreesia during the first quarter worth $169,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Phreesia during the first quarter worth $202,000. Institutional investors and hedge funds own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.